FDA-approved FGFR inhibitors show promise against rare and aggressive pediatric brain tumor

A study led by researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and the Broad Institute of MIT and Harvard has uncovered critical insights into the biology of embryonal tumor with multilayered rosettes (ETMR), a rare and aggressive brain tumor affecting young children.

👉 Full Story